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Abstract
Background: Pacific saury is a common dietary component in East Asia. Saury oil contains considerable levels of
n-3 unsaturated fatty acids (PUFA) and long-chain monounsaturated fatty acids (LCMUFA) with aliphatic tails longer
than 18 carbons. In our previous study, consumption of saury oil for 4 to 6 wk improved insulin sensitivity and the
plasma lipid profile in mice. However, the long-term effects of saury oil on metabolic syndrome (MetS) risk factors
remain to be demonstrated. In the current study, we examined the long-term effects of saury oil on mice fed a high-fat
diet, and compared the effect of n-3 PUFA EPA and LCMUFA on MetS risk factor in diet-induced obese mice.
Methods and Results: In Experiment 1, male C57BL/6 J mice were fed either a 32 % lard diet (control) or a diet
containing 22 % lard plus 10 % saury oil (saury oil group) for 18 weeks. Although no differences were found in
body weight and energy expenditure between the control and saury oil groups, the saury oil diet decreased
plasma insulin, non–HDL cholesterol, hepatic steatosis, and adipocyte size, and altered levels of mRNA transcribed
from genes involved in insulin signaling and inflammation in adipose tissue. Organ and plasma fatty acid profile
analysis revealed that consumption of saury oil increased n-3 PUFA and LCMUFA (especially n-11 LCMUFA) levels
in multiple organs, and decreased the fatty acid desaturation index (C16:1/C16:0; C18:1/C18:0) in liver and adipose
tissue. In Experiment 2, male C57BL/6 J mice were fed a 32 % lard diet (control), a diet containing 28 % lard plus
4 % EPA (EPA group), or a diet containing 20 % lard plus 12 % LCMUFA concentrate (LCMUFA group) for 8 weeks.
EPA or LCMUFA intake increased organ levels of EPA and LCMUFA, respectively. Consumption of EPA reduced
plasma lipid levels and hepatic lipid deposition, and decreased the fatty acid desaturation index in liver and
adipose tissue. Consumption of LCMUFA decreased plasma non–HDL cholesterol, improved hyperinsulinemia, and
decreased the fatty acid desaturation index in adipose tissue. EPA accumulated mainly in liver, and LCMUFA
(especially n-11 LCMUFA) accumulated mainly in white adipose tissue, suggesting their possible individual
biological effects for improving MetS.
Conclusion: Our results suggest that saury oil-mediated improvement of metabolic syndrome in diet-induced
obese mice may possibly be due to a combined effect of n-3 PUFA and LCMUFA.
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Background
Increasing evidence has demonstrated that metabolic
syndrome (MetS) is associated with an increased risk
of cardiovascular disease, the leading cause of death
globally [1]. Diverse factors influence the prevalence
of MetS, but the main factors include diet and other
lifestyle behaviors [2]. The physiological properties of
fatty acids largely depend on the chain length and de-
gree of unsaturation. In general, compared with satu-
rated fatty acid (SFA), polyunsaturated fatty acid
(PUFA) and monounsaturated fatty acid (MUFA) im-
prove protection against MetS and cardiovascular
disease risk factors [3, 4].
Although fish oil is a common source of long-chain n-
3 PUFA including eicosapentaenoic acid (EPA) and doc-
osahexaenoic acid (DHA), some fishes such as saury,
pollock, and salmon also have considerable levels of
long-chain MUFA (LCMUFA) with aliphatic tails longer
than 18 carbons (i.e., C20:1 and C22:1 isomers
combined) [5, 6]. We previously reported that ingestion
of a concentrate of fish oil–derived LCMUFA improves
lipid and glucose homeostasis and adipocyte size in mice
[7, 8]. Therefore, examination of the metabolic effects of
fish oils rich in both n-3 PUFA and LCMUFA is of great
interest. In our previous study, consumption of saury oil
for 4 to 6 weeks improved insulin sensitivity and the
plasma lipid profile in diet-induced obese mice and type
II diabetic mice [9]. However, the long-term effects of
saury oil on MetS risk factors remain to be demon-
strated. Furthermore, since LCMUFA-rich oil consump-
tion up-regulated mRNA expression of genes related to
energy expenditure in diet-induced obese mice [8, 9], es-
timation of the effect of saury oil on metabolic indices is
of great interest.
The aim of this study was to assess the long-term
(18 weeks) effect of feeding saury oil to experimentally
obese (diet-induced) mice with respect to the plasma pa-
rameters for lipid and glucose metabolism, hepatic stea-
tosis, adipocyte size, and resting energy expenditure.
Furthermore, to evaluate the independent roles of n-3
PUFA and LCMUFA in saury oil for improving MetS in
a separate experiment, the same animal model was used,
and mice were fed a high-fat diet supplemented with
EPA or LCMUFA ethyl ester for 8 wk. The plasma lipid
and glucose homeostasis profiles and the hepatic lipid
content were analyzed. Our previous studies have shown
that dietary LCMUFA improved MetS risk factors via
favourable changes in glucose/lipid metabolism-related
gene expression and down-regulation of proinflamma-
tory molecules [7, 8]. In comparison, dietary n-3 PUFA
has been shown in various studies to improve MetS
through multiple mechanisms, including: reducing hep-
atic lipid accumulation, decreasing the fraction of
atherogenic small, dense LDL, and modulating
inflammation and endothelial function [10]. Thus, effects
of n-3 PUFA and LCMUFA may be shared and/or com-
plementary. To the best of our knowledge, very few
studies have compared the effect of fish oil-derived EPA
and LCMUFA on MetS risk factor in MetS animal
models. In the current study, we hypothesized that long-
term feeding of diet-induced obese mice with saury oil
would improve MetS symptoms, and both omega-3 fatty
acid and LCMUFA may be major contributing factors
with shared and complementary mechanisms involved.
Diet-induced obese C57BL/6 mouse was chosen as the
experimental model owing to its similarity with common
features of human MetS [11].
Methods
Materials
Saury oil and fractions of fish oil with given concentra-
tions of ethyl esters of EPA and LCMUFA were produced
by Nippon Suisan Kaisha, Ltd. (Tokyo, Japan). Lard was
purchased from Romi Smilfood B.V. (Heerenveen,
Netherlands). The fatty acid composition of the dietary
oils is shown in Table 1.
Mice and diets
This study consisted of two experiments. In Experiment
1, twenty male C57BL/6 J mice aged 5 weeks were ob-
tained from Japan SLC, Inc. (Shizuoka, Japan). After
acclimatization for a 2-week period, the animals were
assigned to one of two dietary groups (n = 10 per group)
by weight matching. They consumed the experimental
diets ad libitum for 18 weeks. Experimental diets were
based on a standard purified rodent diet (Research Diets,
Inc.) with either lard (control diet; 32 % lard) or saury
oil (saury oil diet; 22 % lard and 10 % saury oil) (Table 2).
The dose of saury oil in this study was consistent with
the dose used in our previous study [9]. At the end of
18 weeks, mice from each group were sacrificed by
injecting sodium pentobarbital (300 mg/kg) intraperito-
neally without fasting.
In Experiment 2, 5-week-old male C57BL/6 J mice (30
total; Japan SLC, Inc.) were acclimatized for a 2-week
period and then assigned to one of three dietary groups
(n = 10 per group). They consumed the experimental di-
ets ad libitum for 8 weeks. Experimental diets were
based on a standard purified rodent diet (Research Diets,
Inc.) with either lard (control diet; 32 % lard), EPA con-
centrate (EPA diet; 28 % lard and 4 % EPA ethyl ester),
or LCMUFA concentrate (LCMUFA diet; 20 % lard and
12 % LCMUFA ethyl ester) (Table 2). At the end of
8 weeks, mice from each group were sacrificed by inject-
ing sodium pentobarbital (300 mg/kg) intraperitoneally
without fasting.
Body weight and food intake were recorded every
week. Retro-orbital bleeds to evaluate plasma lipid
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profiles were performed under isoflurane anesthesia on
mice that had been fasted for 5 h after the acclimation
period (0 week) and after 5, 12, and 18 weeks (Experi-
ment 1) and after 4 and 8 weeks (Experiment 2). At the
end of the intervention period (18 weeks for Experiment
1 and 8 weeks for Experiment 2), mice were anesthetized
with sodium pentobarbital (300 mg/kg) intraperitoneally
in the early light phase of the light-dark cycle and blood
was taken from the abdominal aorta. Plasma was ob-
tained by centrifugation at 1500 × g for 15 min and
stored at −80 °C until further analysis. Mesenteric, epi-
didymal, and subcutaneous white adipose tissue (WAT),
liver, duodenum, and muscle were removed, rinsed with
PBS, weighed, flash frozen, and stored at −80 °C. The
animal protocol was approved by the Animal Care and
Use Committee of Tokushima University and was in ac-
cordance with guidelines provided by the NIH Guide for
the Care and Use of Laboratory Animals.
Measurement of energy expenditure
In Experiment 1, oxygen consumption and CO2 produc-
tion were measured using the Oxymax system (Columbus
Instruments, Columbus, OH, USA) by monitoring indi-
vidual mice in a metabolic cage with free access to food
and drinking water. Oxygen consumption was expressed
as mL/kg BW/h, and the respiratory quotient was
calculated from the ratio of CO2 production/oxygen con-
sumption. Spontaneous locomotor activity was evaluated
during a 12-h dark period. Information on motility was
measured using the ACTIMO system (Shinfactory,
Fukuoka, Japan) by monitoring individual mice with infra-
red beams.
Measurement of plasma and organ fatty acid
compositions
At the end of each experiment, lipids were extracted
from mesenteric, epididymal, and subcutaneous WAT,
liver, duodenum, muscle, or plasma followed by methyla-
tion, and fatty acid methyl ester (FAME) were quantified
with gas chromatography as described [12]. In brief, the
total lipids from each organ or plasma were extracted in
a 4:1 (v/v) of methanol:hexane solution, followed by
methylation with acetyl chloride at 80 °C for 1 hr. Fatty
acid (FA) methyl esters were separated using a DB-WAX
capillary column (Agilent Technologies) then quantified
using gas chromatography (Agilent Technologies). Peaks
of FAME were identified by comparison with purified
standards Nu-Chek Prep (Elysian, MN, USA) and
expressed as the percentage of total fatty acids.
Table 1 Fatty acid composition of the dietary oils incorporated
into the diets of the mice
Fatty acids (%) Lard Saury oil EPA LCMUFA
SFA 33 21 0.0 19.7
14:0 1.5 6.6 0.0 3.5
16:0 25.4 12.5 0.0 12.8
18:0 5.9 1.7 0.0 3.0
20:0 0.2 0.2 0.0 0.4
MUFA 45.8 33.4 0.0 63.9
16:1(n-7) 2.4 5.6 0.0 1.3
18:1(n-9) 43.2 6.3 0.0 4.8
20:1(n-11) 0.0 7.4 0.0 16.8
20:1(n-9) 0.2 2.5 0.0 4.7
22:1(n-11) 0.0 11.0 0.0 34.8
22:1(n-9) 0.0 0.6 0.0 1.5
n-6 PUFA 10.8 2 0.0 0.9
18:2(n-6) 10.8 1.4 0.0 0.8
20:4(n-6) 0.0 0.6 0.0 0.1
n-3 PUFA 1.1 26 96.8 1.1
18:3(n-3) 1.0 1.3 0.0 0.3
20:5(n-3) 0.0 11.1 96.8 0.2
22:5(n-3) 0.1 1.3 0.0 0.2
22:6(n-3) 0.0 12.3 0.0 0.4
Table 2 Composition of diets enriched with either lard
(control), saury oil, EPA, or LCMUFA fed to mice for 18 or
8 weeks
Experiment 1 Experiment 2
Ingredient (g/kg) Lard Saury oil EPA LCMUFA
Casein 258 258 258 258
L-cysteine 4 4 4 4
Maltodextrin 10 162 162 162 162
Sucrose 89 89 89 89
Cellulose 65 65 65 65
Mineral mixture 13 13 13 13
Vitamin mixture 13 13 13 1.3
Choline bitartrate 3 3 3 3
Soybean oil 32 32 32 32
Experimental oils
Lard 320 220 280 200
Saury oil 0 100 0 0
EPA 0 0 40 0
LCMUFA 0 0 0 120
Nutritional values
Energy content, MJ/kg 23 23 23 23
Protein, % of energy 14 14 14 14
Carbohydrate, % of energy 26 26 26 26
Fat, % of energy 60 60 60 60
Experiment 1, mice were fed diets enriched with lard or saury oil for 18 weeks;
Experiment 2, mice were fed diets enriched with lard, EPA, or LCMUFA
for 8 weeks
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Plasma biochemical analyses
At a determined time point for each experiment, fasting
plasma samples collected in heparinized capillary tubes
from the retro-orbital sinus were analyzed for plasma
triglyceride (TG), total cholesterol (TC), HDL choles-
terol (HDL-C), and glucose concentrations, using a
Triglyceride E-Test, a Cholesterol E-Test, an HDL Chol-
esterol E-Test, and a Glucose CII-Test, respectively
(Wako Pure Chemical Industries, Ltd., Osaka, Japan), re-
spectively. Plasma insulin concentrations were deter-
mined with an ELISA kit (Morinaga Institute of
Biological Science, Inc., Yokohama, Japan).
Measurement of liver lipid levels
At the end of each experiment, hepatic lipids were ex-
tracted from the liver according to Folch et al. [13]. The
dried lipid residues were dissolved in 2-propanol contain-
ing 10 % (w/w) Triton X-100 for the TG and cholesterol
assays. The hepatic TG and TC contents were measured
with the Triglyceride E-Test and Cholesterol E-Test, re-
spectively. Furthermore, hepatic lipid deposits in Experi-
ment 1 were visualized by staining with hematoxylin and
Oil Red O on 10-μm thick cryosections.
Determination of adipocyte size
At the end of Experiment 1, distribution of the adipocyte
size in Experiment 1 was determined as described [14].
Briefly, adipocytes isolated from epididymal and sub-
cutaneous WAT were fixed with 2 % osmium tetroxide
and passed through a 250-μm nylon filter to remove the
fibrous tissue. The cells were then washed extensively
with isotonic saline. Ten thousand cells were analyzed
using the Coulter Multisizer III (Beckman Coulter, High
Wycombe, England).
RNA isolation and real-time PCR
At the end of Experiment 1, total RNA was prepared
from epididymal adipose tissue using the QIAzol lysis
reagent (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions, and the RNA concentration was
determined by measuring the absorbance at 260 nm.
RNA from each sample was assessed for purity by A260/
280 ratios, and the integrity of the RNA was verified by
agarose gel electrophoresis. Real-time PCR was per-
formed as described [7]. In brief, primers for insulin re-
ceptor substrate (Irs), insulin receptor (Insr), tumor
necrosis factor alpha (Tnf-alpha), and matrix metallo-
peptidase 3 (Mmp3) are listed in Table 3. Real-time PCR
was performed on an 300 Real-Time PCR System (Life
Technologies Co., Japan) using SYBR Premix Ex Taq
(Takara Bio Inc., Otsu Shiga, Japan), while mouse beta-
actin served as the housekeeping gene. The PCR cycling
conditions were as follows: 30 s at 95 °C; followed by
40 cycles of 5 s at 95 °C, 34 s at 60 °C; and a final melt-
ing curve of 15 s at 95 °C, 1 min at 60 °C, 15 s at 95 °C.
Statistical analysis
Data for Experiment 1 were collected at the 0-, 5-, 12-,
or 18-week time point, and the Student’s t-test was used
for statistical analysis of the control versus saury oil
treatment group. Data for Experiment 2 were collected
at the 4- or 8-week time point, and ANOVA followed by
Tukey’s test for multiple comparisons was used to iden-
tify significant differences among the control, EPA, and
LCMUFA treatment groups. Analyses were performed
using Prism software (GraphPad Software, San Diego,
CA, USA), and P values <0.05 were considered statisti-
cally significant. Data are the mean ± SEM.
Results
Experiment 1
Food intake and body weight
All mice remained healthy throughout the 18-week feed-
ing period. We found no significant differences in food in-
take (control: 2.6 ± 0.1 g/mouse/day vs. saury oil group:
2.4 ± 0.1 g/mouse/day) or final body weight (control: 43.7
± 0.6 g vs. saury oil group: 43.4 ± 0.5 g) between the con-
trol and saury oil groups (Additional file 1).
Metabolic indices
Oxygen consumption, respiratory quotient, and spontan-
eous locomotor activity did not differ between the two
diets at the 0-, 5-, 12-, or 18-week time points (Fig. 1).
Furthermore, for oxygen consumption, there were no
significant differences between each measuring time
point in both control and saury oil group. For respiratory
quotient, compared with week 0, week 5, it decreased sig-
nificantly (P < 0.001) at week 5, 12, and 18 in either con-
trol or saury oil group. For locomotor activity, compared
with week 0, it decreased significantly (P < 0.001) at week
12 and 18 in either control or saury oil group.
Plasma and organ fatty acid compositions
The fatty acid composition in WAT, liver, duodenum,
muscle, and plasma reflected the composition of the oils
present in the diets (Fig. 2). Although mice fed saury oil
had a similar proportion of SFA compared with mice fed
the control diet, total n-3 PUFA levels were higher
(~0.5- to 3-fold) in each estimated organ/plasma in the
saury oil group compared with the control. In contrast,
saury oil consumption decreased the percentages of total
MUFA (~5–20 %) and n-6 PUFA (~7–32 %) in each esti-
mated organ/plasma. Changes in individual MUFA levels
differed according to chain length (Fig. 3). Mice fed the
saury oil diet had proportionally more LCMUFAs (~0.1-
to 3.6-fold) and less 16:1(n-7) (~7–23 %) and 18:1(n-9)
(~7–20 %) than the control diet group in each estimated
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organ/plasma. For individual types of LCMUFA, as com-
pared with the control group, the changes in n-11
LCMUFA (C20:1 n-11, ~16 to 180-fold; C22:1 n-11, ~6
to 56-fold increase) were larger than than changes in n-9
LCMUFA (C20:1 n-9, ~0.2 to 0.8-fold; C22:1 n-9, ~0.4
to 2.8-fold increase) in each estimated organ/plasma
(Fig. 4). Furthermore, our data showed that saury oil
consumption suppressed fatty acid desaturation indexes
16:1/16:0 by ~7–15 % (P < 0.05) and 18:1/18:0 by ~11–
33 % (P < 0.05) in WAT and liver (Fig. 5a), along with
decreases in 16:1 and 18:1 levels.
Plasma glucose and lipid metabolism
At 18 weeks, although the plasma glucose levels of mice
fed saury oil were not different from those fed the con-
trol diet (Control: 18.9 ± 1.6 mmol/L vs. Saury oil group:
16.7 ± 1.1 mmol/L), plasma insulin levels decreased by
38 % (P < 0.05) with intake of saury oil (Fig. 6a). At base-
line, no differences were found for plasma lipid levels
between the control and saury oil groups (Table 4).
Although there were no differences in plasma TG levels,
mice fed the saury oil diet had significantly lower total
cholesterol (TC) (P < 0.05), non–HDL cholesterol (non-
HDL-C) (P < 0.05), and TC:HDL-C ratio (P < 0.05) at the
5-, 12-, and 18-week time points compared with control
mice.
Liver lipid concentrations
At 18 weeks, although we found no differences in liver
weight between the control and saury oil groups (Con-
trol: 4.5 ± 0.5 g/100 g liver vs. Saury oil group: 4.5 ±
0.3 g/100 g liver), hepatic TG concentrations were sig-
nificantly lower by 29 % (P < 0.05) in the saury oil group
compared with the control (Fig. 7a). This result was fur-
ther confirmed by Oil Red O staining, which showed a
decrease in hepatic lipid deposition in saury oil–fed mice
compared with control mice (Additional file 2). Hepatic
cholesterol concentrations were not different between
the two groups.
Adipocyte size
At 18 weeks, the mean adipocyte size in epididymal adi-
pose tissue was about 10 % smaller (P < 0.05) in the
saury oil group compared with the control (Fig. 8a). We
found a non-significant decrease (4 %) in the mean adi-
pocyte size in subcutaneous adipose tissue (Fig. 8b).
mRNAs transcribed from genes related to insulin signaling
and inflammation in WAT
Levels of mRNAs transcribed from Irs and Insr (Fig. 9a),
which are involved in insulin signaling, were significantly
increased (P < 0.05) by the saury oil diet. mRNA levels of
Tnf-alpha (Fig. 9b), which are mediators of inflamma-
tion, was significantly decreased (P < 0.05) by the saury
oil diet. We also measured Mmp3 expression, but there
was no significant difference (P = 0.15) between the con-
trol and saury oil group (Fig. 9b).
Experiment 2
Food intake and body weight
Food intake (control: 2.6 ± 0.4 g/mouse/day vs. EPA group:
2.6 ± 0.2 g/mouse/day vs. LCMUFA group: 2.6 ± 0.3 g/
mouse/day) and final body weight (control: 35.1 ± 0.6 g vs.
EPA group: 35.2 ± 0.5 g vs. LCMUFA group: 34.9 ± 0.4 g)
did not differ among mice fed the control, EPA, or
Table 3 Oligonucleotide primers used for RNA analysis
Gene Accession number Forward primer Reverse primer
Irs NM_010570 TCTACACCCGAGACGAACACT TGGGCCTTTGCCCGATTATG
Insr NM_010568 ATGGGCTTCGGGAGAGGAT CTTCGGGTCTGGTCTTGAACA
Tnf-alpha NM_013693 CAGGCGGTGCCTATGTCTC CGATCACCCCGAAGTTCAGTAG



































































Fig. 1 Energy expenditure in diet-induced obese C57BL/6 J mice fed
the control or saury oil diet for 18 weeks. Oxygen consumption (a),
respiratory quotient (b) and spontaneous locomotor activity (c) at
baseline, 5, 12 and 18 weeks. Values are means ± SEM, n = 10
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LCMUFA diets. In addition, there were also no significant
differences in body weight between the three groups dur-
ing the 8-week feeding period (Additional file 1).
Plasma and organ fatty acid compositions
As expected, the fatty acid composition in liver and
WAT also reflected the dietary perturbations (Fig. 10). In
general, mice fed the EPA diet had proportionally more
EPA (~14- to 49-fold) than the control and LCMUFA-
fed groups, and proportionally more LCMUFAs (~2- to



















































































Fig. 2 Organ and plasma fatty acid compositions in diet-induced
obese C57BL/6 J mice fed the control or saury oil diet for 18 weeks.
Percentages of total SFA (a), total MUFA (b), total n-6 PUFA (c), total n-
3 PUFA (d) in total lipids of WAT, liver, duodenum, muscle, and plasma
at the end of 18 weeks. Values are means ± SEM, n = 10. *P < 0.05, **P
< 0.01, ***P < 0.001 vs. control group. SAF, saturated fatty acids; MUFA,
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; MWAT,
mesenteric white adipose tissue; EWAT, epididymal white adipose tis-


































































Fig. 3 Organ and plasma levels of MUFA in diet-induced obese
C57BL/6 J mice fed the control or saury oil diet for 18 weeks.
Percentages of palmitoleic acid (a), oleic acid (b) and LCMUFA (c) in
total lipids of WAT, liver, duodenum, muscle, and plasma at the end
of 18 weeks. Values are means ± SEM, n = 10. *P < 0.05, **P < 0.01,
***P < 0.001 vs. control group. MWAT, mesenteric white adipose
tissue; EWAT, epididymal white adipose tissue; SWAT, subcutaneous
white adipose tissue
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with control or EPA groups. For individual types of
LCMUFA, there were no significant differences between
the control and EPA group. In general, compared with
the control or EPA group, each type of LCMUFA had a
greater fold change (~1.3 to 205-fold increase) in WAT
than in liver (~0.05 to 161-fold increase). Also, as
compared with the control or EPA group, the changes in
n-11 LCMUFA (C20:1 n-11, ~18 to 161-fold; C22:1 n-
11, ~41 to 205-fold increase) were greater than for n-9
LCMUFA (C20:1 n-9, ~0.05 to 1.5-fold; C22:1 n-9, ~0.4
to 12-fold increase) in WAT and liver tissues (Fig. 11).
Furthermore, both the EPA and LCMUFA diets de-
creased the ratios of C16:1/C16:0 (~7–15 %) (P < 0.05)
and C18:1/C18:0 (~11–33 %) (P < 0.05) in WAT as com-
pared with the control group, and the EPA diet de-
creased the ratio of C16:1/C16:0 by 28 % (P < 0.05) and
C18:1/C18:0 by 62 % (P < 0.05) in the liver (Fig. 5b).
Plasma glucose and lipid metabolism
At 8 weeks, plasma insulin levels were significantly
(57 %) (P < 0.05) lower in the LCMUFA diet group than
in the control group, although no statistically significant
difference was found between the control and EPA diet
groups (Fig. 6b). We found no differences in plasma glu-
cose concentrations among the dietary groups (data not
shown). Concerning the plasma lipid profile, the EPA
diet decreased plasma TG levels by 49 % (P < 0.05) by
the end of 4 weeks, and no differences in plasma TG
concentrations were found between the control and
LCMUFA diet groups (Table 5). Plasma levels of TC,
non–HDL-C, and the TC:HDL-C ratio in mice fed the
EPA or LCMUFA diets were lower (P < 0.05) than in































Fig. 4 Organ and plasma levels of individual types of LCMUFA in
diet-induced obese C57BL/6 J mice fed the control or saury oil
diet for 18 weeks. Percentages of C20:1 n-9 (a), C20:1 n-11 (b),
C22:1 n-9 (c) and C22:1 n-11 (d) in total lipids of WAT, liver,
duodenum, muscle, and plasma at the end of 18 weeks. Values
are means ± SEM, n = 10. **P < 0.01, ***P < 0.001 vs. control group.
MWAT, mesenteric white adipose tissue; EWAT, epididymal white
adipose tissue; SWAT, subcutaneous white adipose tissue
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Fig. 5 Lipid desaturation index in diet-induced obese C57BL/6 J mice.
Ratio of 16:1/16:0 (left panels) and 18:1/18:0 (right panels) in epididymal
WAT and liver at the end of 18 weeks in mice fed diets enriched in lard
or saury oil (a) and at the end of 8 weeks in mice fed diets enriched in
lard, EPA, or LCMUFA (b). Values are means ± SEM, n = 10. Significantly
different mean values (P < 0.05) are indicated by different lowercase
letters. WAT, white adipose tissue
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points. In addition, although EPA consumption signifi-
cantly decreased (P < 0.05) the plasma HDL-C concen-
tration at the 4- and 8-wk time points, we found no
difference in plasma HDL-C levels between the control
and LCMUFA diet groups.
Liver lipid concentrations
Mice fed the EPA diet had significantly lower (P < 0.05)
hepatic TG compared with the control or LCMUFA
groups (Fig. 7b). Hepatic TG concentrations did not dif-
fer between the control and LCMUFA groups. Hepatic
cholesterol levels did not differ among the three groups.
Discussion
The lipid content and fatty acid profile of fish vary
largely among species, and consumption of certain spe-
cies provides high levels of LCMUFAs in addition to n-3
PUFAs. The Pacific saury is common in the diets of East
Asians, and the adult saury has a high lipid content
(~12–22 %) with concomitantly high levels of long-chain
n-3 PUFAs and LCMUFAs. Although many beneficial ef-
fects of n-3 PUFA–rich fish oils have been demon-
strated, the ability of fish oil rich in LCMUFAs in
addition to n-3 PUFAs to attenuate MetS risk factors
has not been well studied. Although our previous studies
show that saury oil-supplemented diet (4 ~ 6 wk)
improved MetS risk factors in MetS mice models, the
long-term effect of saury oil on MetS risk factors, energy
expenditure, and accumulation of LCMUFA in each
organ has not been fully studied yet. Furthermore, very
few studies in the literature have compared the effects of
EPA and LCMUFA that are enriched in saury oil. In the
present study, we demonstrated that feeding with saury
oil for 18 weeks ameliorated diet-induced hyperinsuline-
mia, dyslipidemia, fatty liver, and adipocyte hypertrophy
in mice, although the saury oil diet did not alter the en-
ergy expenditure. The saury oil diet resulted in signifi-
cant increases in n-3 PUFAs and LCMUFAs, especially
n-11 LCMUFAs, in plasma and vital organs, suggesting
a possible involvement of these fatty acids in the benefi-
cial effect of saury oil on MetS. In fact, compared with
the control diet, EPA ingestion attenuated hyperlipid-
emia and hepatic fat accumulation, and LCMUFA inges-
tion improved hyperinsulinemia and hyperlipidemia in
the same mouse model of MetS. In addition, the EPA-
rich diet resulted in a significant increase in EPA mainly
in liver, and the LCMUFA-rich diet resulted in a signifi-

















































Fig. 6 Plasma insulin concentrations in diet-induced obese C57BL/
6 J mice. Plasma insulin concentrations at the end of 18 weeks in
mice fed diets enriched in lard or saury oil (a) and at the end of
8 weeks in mice fed diets enriched in lard, EPA, or LCMUFA (b).
Values are means ± SEM, n = 10. Significantly different mean values
(P < 0.05) are indicated by different lowercase letters
Table 4 Plasma lipid profile at baseline (0 week) and at 5, 12,
and 18 weeks of feeding mice diets enriched with (control) or
saury oil
Dietary oils
Lipid Lard Saury oil
0 week mmol/L
TG 1.3 ± 0.2 1.1 ± 0.1
TC 2.7 ± 0.2 2.7 ± 0.1
non–HDL-C 1.4 ± 0.1 1.3 ± 0.1
HDL-C 1.3 ± 0.1 1.4 ± 0.1
TC:HDL 2.1 ± 0.1 1.9 ± 0.1
5 weeks
TG 1.2 ± 0.1 1.0 ± 0.1
TC 4.3 ± 0.3 3.3 ± 0.1**
non–HDL-C 2.2 ± 0.1 1.4 ± 0.1 **
HDL-C 2.1 ± 0.1 1.9 ± 0.1
TC:HDL 2.1 ± 0.1 1.7 ± 0.03*
12 weeks
TG 0.9 ± 0.2 0.6 ± 0.1
TC 4.5 ± 0.2 3.6 ± 0.1 **
non–HDL-C 2.3 ± 0.2 1.5 ± 0.3 *
HDL-C 2.2 ± 0.1 2.1 ± 0.1
TC:HDL 2.1 ± 0.1 1.7 ± 0.02*
18 weeks
TG 0.4 ± 0.04 0.4 ± 0.1
TC 4.3 ± 0.3 3.9 ± 0.2
non–HDL-C 2.5 ± 0.2 2.0 ± 0.1*
HDL-C 1.8 ± 0.1 1.9 ± 0.1
TC:HDL 2.4 ± 0.1 2.0 ± 0.1*
Values are means ± SEM, n = 10. *P < 0.05, **P < 0.01 compared with control. TG
triglyceride, TC total cholesterol, HDL-C HDL cholesterol
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mainly in WAT. The accumulation of EPA and
LCMUFA in different organs suggested their possible in-
dividual biological effects for improving MetS.
Many features of MetS are associated with insulin re-
sistance, which is related to hyperinsulinemia. A previ-
ous study in mice infused with insulin suggested that
basal hyperinsulinemia also leads to generalized insulin
resistance [15]. In the current study, consumption of
both saury oil and an LCMUFA concentrate improved
hyperinsulinemia in obese mice; these data are consist-
ent with our previous research, which indicated a benefi-
cial effect of LCMUFA-rich oil on insulin sensitivity in
the MetS mouse model [7–9]. Dyslipidemia, which is
also a consequence of insulin resistance, is characterized
by increased blood levels of LDL-C, reduced HDL-C,
and increased TGs. High serum cholesterol is considered
to be a strong risk factor for atherosclerosis, and
cholesterol-lowering treatment is the gold standard pre-
ventive strategy for cardiovascular disease [16]. Further-
more, elevated non–HDL-C signifies an increased risk of
cardiovascular disease, and the TC:HDL-C ratio is a reli-
able measure of cardiovascular disease [17, 18]. Al-
though intake of saury oil did not alter plasma HDL-C
and TG levels after 18-week feeding, plasma TC, non–
HDL-C levels, and the TC:HDL-C ratio tended to
decrease compared with the control diet group. Note-
worthily, n-3 PUFA-rich oils generally are supposed to
reduce elevated plasma TG levels in human and rodents
[19], but we did not observe changes in plasma TG con-
centration between the control and saury oil groups,
probably due to the small dose of n-3 PUFA contained
in saury oil (equivalent to ~2 % of EPA plus DHA). Simi-
larly, Mori et al. also reported that no plasma TG
changes were observed even when used a relatively high
dose of n-3 PUFA-rich fish oil (equivalent to ~4 % of
EPA plus DHA) in an experiment feeding mice a high-
fat diet for 5 months [20]. Similar plasma lipid patterns
were observed in mice fed EPA or LCMUFAs for 8 wk.
Relative to the SFA-rich lard diet, both dietary EPA and
LCMUFA decreased plasma cholesterol, and EPA low-
ered non–HDL-C more than LCMUFA did. This finding
confirms previous observations that consumption of
PUFA or MUFA can lower plasma cholesterol concen-
trations more so than can SFA [21]. Our results are also
consistent with studies feeding mice with either a high
fat diet or a high fat diet supplemented with n-3 PUFA-
rich fish oil, in which fish oil (equivalent to ~4 % of n-3
PUFA) significantly decreased plasma cholesterol levels.
The mechanisms underlying the hypocholesterolemic ef-
fect of dietary PUFAs or MUFAs may include upregula-
tion of activity or mRNA levels of the LDL receptor,
sterol regulatory element–binding protein 2, and micro-
somal triglyceride transfer protein [22, 23]. In addition,
































































Fig. 8 Adipocyte size in diet-induced obese C57BL/6 J mice fed the
control or saury oil diet for 18 weeks. Adipocyte size in epididymal
adipose (a) and subcutaneous adipose (b) tissue at the end of
18 weeks. The left panels indicate the frequency distribution of
adipocyte size, and the right panels indicate the mean size of



























































Fig. 7 Liver lipid concentrations in diet-induced obese C57BL/6 J
mice. Liver lipid concentrations at the end of 18 weeks in mice fed
diets enriched in lard or saury oil (a) and at the end of 8 weeks in
mice fed diets enriched in lard, EPA, or LCMUFA (b). Values are
means ± SEM, n = 10. Significantly different mean values (P < 0.05)
are indicated by different lowercase letters
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decreased plasma TC with a concomitant decrease in
HDL-C, dietary LCMUFAs did not decrease HDL-C,
which is consistent with our previous study [7]. le Mor-
van et al. reported that an n-3 PUFA–enriched diet de-
creases plasma HDL-C levels in mice, probably owing to
an increase in the amount of scavenger receptor class B-
1 in liver [24]. A human study also demonstrated differ-
ent responses of HDL-C to diets of n-3 PUFA–rich tuna
and n-3 PUFA– and LCMUFA-rich salmon [25]. Al-
though the lipoprotein response to LCMUFAs has not
been well studied, the shorter-chain MUFA 18:1(n-9) de-
creases plasma LDL-C levels without lowering HDL-C
when fed to humans [26, 27].
Studies have demonstrated that a high-fat diet triggers
lipid deposits in liver, and the intrahepatic fat content
appears to be tightly related to MetS [28]. Consistent
with our histologic observations, biochemical analysis
showed that the TG level was greatly reduced in the
livers of saury oil–fed mice compared with those of mice
fed the lard diet. Furthermore, feeding mice with EPA,
but not LCMUFA, significantly decreased hepatic TG
concentration. Our study is consistent with the study of
Sato et al. [29] who reported that dietary supplementa-
tion with EPA strongly suppresses obesity-related ele-
vated hepatic TG content and lipogenic enzymes.
Reductions in mRNA and the active protein of sterol
regulatory element binding protein-1c (SREBP-1c) may
be one of the major mechanisms responsible for the ef-
fect of EPA on improving fatty liver [30]. Stearoyl-CoA
desaturase-1 (SCD-1) catalyzes the synthesis of MUFAs
from saturated fatty acids. The MUFA to saturated fatty
acid ratio, particularly C16:1/C16:0 and C18:1/C18:0, af-
fects membrane phospholipid composition, and studies
have indicated that alteration in this ratio has been in-
volved in multiple MetS-related diseases, such as dia-
betes and cardiovascular disease [31] Therefore, the
activity of SCD-1 is important in MetS states. Decreased
SCD-1 activity is actually associated with improved adi-
posity and insulin sensitivity, and n-3 PUFAs inhibit ex-
pression of Scd-1 in mouse liver [32–34]. In the current
study, saury oil and EPA significantly decreased SCD-1
desaturation index (C16:1/C16:0 and C18:1/C18:0) in
liver and WAT tissues, and LCMUFA decreased these
SCD-1 desaturation index only in WAT but not liver.
Therefore, the effect of saury oil on improving hepatic
steatosis may possibly be attributed to EPA and may
partly be due to inhibition of SCD-1 activity. On the
other hand, the absence of a change in the desaturation
index in liver by dietary LCMUFAs may at least partly
explain the lack of improvement in hepatic lipid depos-
ition. This is probably due to a less accumulation of

































































































Fig. 10 Organ fatty acid compositions in diet-induced obese C57BL/
6 J mice fed the control, EPA or LCMUFA diet for 8 weeks. Fatty acid
composition in liver (a) and epididymal adipose tissue (b) at the end
of 8 weeks. Values are means ± SEM, n = 10. Significantly different




















































Fig. 9 Gene expressions in adipose tissue of diet-induced obese
C57BL/6 J mice fed the control or saury oil diet for 18 weeks.
mRNAs transcribed from insulin signaling–related genes (a) and
pro-inflammatory genes (b) in epididymal adipose tissue at the
end of 18 weeks. Values are means ± SEM, n = 10. *P < 0.05 vs.
control group
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Adipose tissue is a highly active endocrine organ with
the capacity to produce various bioactive mediators that
modulate hemostasis, lipid and glucose metabolism, and
inflammation [35]. Inflammatory cytokines associated
with hypertrophic adipocytes may contribute to the de-
velopment of many aspects of MetS and insulin resist-
ance. The saury oil diet decreased adipocyte size, with
concomitant increases in mRNAs transcribed from insu-
lin signaling genes (Irs and Insr) and decreases in
mRNAs transcribed from pro-inflammatory genes (Tnf-
alpha and Mmp3). Thus, the beneficial effects of saury
oil on plasma glucose and lipid homeostasis may be
partly linked to morphologic and inflammatory changes
in adipose tissue. Previous studies have also shown that
a diet rich in EPA or LCMUFA reduces adipocyte size
and improves adipose inflammation in mice [7, 8, 35].
Because saury oil, EPA, or LCMUFA consumption low-
ered the ratios of 16:1/16:0 and 18:1/18:0 in adipose tis-
sue, both EPA and LCMUFAs may contribute to the
beneficial effect of saury oil on adipocyte hypertrophy
that may be partially due to decreased SCD-1 activity.
Obesity-related metabolic diseases are associated with
decreased energy expenditure. In the current study, we
also observed a significant time-dependent decrease in
respiratory quotient and locomotor activity with high-fat
diet. A 15 % (w/w) EPA-supplemented diet increases
oxygen consumption and improves the respiratory quo-
tient in high-fat diet–induced obese mice [36]. N-3
PUFA–rich saury oil consumption, however, did not
alter parameters of energy expenditure in our study. The
smaller dose of EPA [1 % (w/w)] in the saury oil diet and
the different animal model used in the present study
may be possible explanations for these differences.
Our data showed LCMUFA may improve serum lipid
levels and potentially prevent diet-induced dyslipidemia,
suggesting the potential application of LCMUFA-rich
fish oil as nutraceuticals in overcoming the negative
effects of lipid disorders. Statin drugs are widely
Table 5 Plasma lipid profile at 4 and 8 weeks of feeding mice
diets enriched with lard (control), EPA, or LCMUFA
Dietary oils
Lipid Lard EPA LCMUFA
4 wk mmol/L
TG 0.8 ± 0.1a 0.4 ± 0.1b 0.9 ± 0.1a
TC 4.5 ± 0.1a 2.9 ± 0.1b 3.6 ± 0.1c
non–HDL-C 2.5 ± 0.1a 1.1 ± 0.04b 1.6 ± 0.1b
HDL-C 2.1 ± 0.1a 1.8 ± 0.1b 2.2 ± 0.1a
TC:HDL 2.1 ± 0.1a 1.6 ± 0.02b 1.6 ± 0.03b
8 wk
TG 0.8 ± 0.2 0.5 ± 0.1 0.6 ± 0.1
TC 4.1 ± 0.1a 2.7 ± 0.1b 3.7 ± 0.1c
non–HDL-C 2.4 ± 0.1a 1.1 ± 0.1b 1.6 ± 0.1b
HDL-C 1.9 ± 0.04a 1.6 ± 0.04b 2.0 ± 0.1a
TC:HDL 2.2 ± 0.1a 1.7 ± 0.1b 1.9 ± 0.03c
Values are means ± SEM, n = 10. Means in a row with superscripts without a

















































Fig. 11 Organ LCMUFA compositions in diet-induced obese C57BL/6 J
mice fed the control, EPA or LCMUFA diet for 8 weeks. Percentages of
C20:1 n-9 (a), C20:1 n-11 (b), C22:1 n-9 (c) and C22:1 n-11 (d) in total
lipids of WAT and liver at the end of 18 weeks. Values are means ±
SEM, n = 10. Significantly different mean values (P < 0.05) are indicated
by different lowercase letters. WAT, white adipose tissue
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considered as successful lipid-lowering therapeutic
agents that reduce the risks associated with cardiovascu-
lar disease. However, due to many adverse side effects,
such as muscle problems, diabetes and increased cancer
risk, alternative lipid-lowering therapy should be consid-
ered [37]. Scicchitano et al. have reviewed the role of
nutraceuticals and functional foods in the management
of dyslipidemia, and showed the beneficial role of fish oil
(alone or in combination with statins) as a nutraceutical
in dyslipidaemia treatment in both animals and humans
[38]. Noteworthily, most fish oils used in these studies
were rich in n-3 PUFA, and our findings from animal
studies offer new insight into fish oils that are enriched
in LCMUFA. Nevertheless, further studies are needed to
elucidate the influence of LCMUFA-rich fish oil as
nutraceuticals for lipid lowering in humans.
There are some limitations in our study. First, due to
lack of a chow-diet control group, we could not quanti-
tatively determine how much saury oil improved MetS.
Additionally, while the significant decreases in plasma
insulin concentration on the saury oil diet is likely due
to a decrease in obese-related insulin resistance, glucose
tolerance tests will be necessary in future studies to ver-
ify the effects of EPA- and LCMUFA-rich oils on insulin
resistance. In addition, because the LCMUFA-rich oil
used in the current study is a mixture of LCMUFA iso-
mers, investigation of the effects of specific isomers will
be necessary in future studies.
Conclusion
In our long-term (18 wk) feeding study, saury oil
enriched in n-3 PUFA and LCMUFA significantly im-
proved risk factors for metabolic syndrome in diet-
induced obese mice, by possible combined effects of
EPA and LCMUFA on altering plasma lipid levels, as
well as by other mechanisms, such as favourable
changes on hepatic lipid deposition, plasma insulin
levels, and the fatty acid desaturation index in adipose
tissue. Our results suggest that both n-3 PUFA and
LCMUFA may contribute to saury oil-mediated im-
provement of metabolic syndrome with shared and
complementary mechanisms.
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